Trifluoperazine (TFP), as an inhibitor of DR2, promotes the degradation of HIF1a.Thus, DR2 may promote the progression of psychological stress-induced malignancies by activating the oxygen-independent HIF1a pathway, while TFP may serve as a potential therapeutic option for cancer patients (65). This evidence concerns the gene HIF1A and cancer.